Anti-HCV prevalence in the general population of Lithuania

Liakina, Valentina; Valantinas, Jonas

doi:10.12659/msm.882511

Cited by 13 publications

(14 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A national seroprevalence survey was underway in Lithuania in 2010 – 2013. Although initial results from 2010 (anti‐HCV prevalence of 2.85% among adults) have been published , there has been concern that the individuals seeking free testing in this first year were more likely to be at high risk of infection (Liakina 2015 personal communication). Preliminary results including 2010 and going through 2013 are currently unpublished but suggest an anti‐HCV prevalence of 1.96% (1.21 – 2.71%) in adults 18–81 years of age (Liakina 2015 personal communication).…”

Section: Resultsmentioning

confidence: 99%

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Liakina

Salehiniya

Tanaka

et al. 2015

Journal of Viral Hepatitis

118

View full text Add to dashboard Cite

SUMMARY. Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates were gathered from the literature and validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Iran and Lebanon to 4.2% in Pakistan. The largest viraemic populations were in Pakistan (7 001 000 cases) and Indonesia (3 187 000 cases). Injection drug use (IDU) and a historically unsafe blood supply were major risk factors in most countries. Diagnosis, treatment and liver transplant rates varied widely between countries. However, comparison across countries was difficult as the number of cases changes over time. Access to reliable data on measures such as these is critical for the development of future strategies to manage the disease burden.

show abstract

Section: Resultsmentioning

confidence: 99%

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Liakina

Salehiniya

Tanaka

et al. 2015

Journal of Viral Hepatitis

118

View full text Add to dashboard Cite

show abstract

“…In developed countries, one factor that is responsible for the increased HCC incidence is HCV [ 3 ]. In Lithuania, anti-HCV prevalence in adults stands at about 2.78% [ 4 ]. HCV-induced HCC development is a multi-step process that may last 20–40 years and involves chronic hepatic inflamma tion, progressive liver fibrosis, initiation of neoplastic clones, and tumor progression in a carcinogenic tissue microenvironment [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C VirusAssociated Hepatocellular Carcinomas

et al. 2017

View full text Add to dashboard Cite

The expression levels of the two novel oncoproteins uridine-cytidine kinase like-1 (UCKL-1) and mitochondrial ribosomal protein S18-2 (MRPS18-2) were assessed in samples of hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) using immunohistochemistry. Tissue microarray (TMA) paraffin blocks were prepared from 42 HCC tumor samples with the corresponding peri-tumor tissues and from 11 tissues of a liver with HCV-induced cirrhosis. We found that the UCKL-1 signal in the liver tissues of the peri-tumor zone in the HCC samples was stronger than that in cirrhosis (50 ± 49.44 vs. 24.27 ± 14.53; p = 0.014). The MRPS18-2 expression was weak, and there was no differences between the groups (p = 0.26). Noteworthy, the UCKL-1 protein was expressed at higher levels in peri-tumor tissues in the cases of HCC recurrence; this was confirmed for 27 older patients (63.78 ± 9.22 vs. 53.53 ± 4.07 years, p < 0.001), in parallel with enhanced UCKL-1 staining in former HCC nodules (62.69 ± 50.4 vs. 26.0 ± 30.19, p = 0.006) and microvascular invasion (p = 0.02). A multivariate analysis of prognostic factors for HCC recurrence showed that the best predictive factors for these conditions were UCKL-1 expression in tumor, vascular invasion, and HCC treatment modality, other than liver transplantation (odds ratios: 1.029, 18.143 and 11.984, R2 = 0.633, p = 0.002). In conclusion, the high UCKL-1 expression might be a prognostic factor for HCC relapse, in combination with age and microvascular invasion. MRPS18-2 protein expression has no prognostic significance in the cases of HCV-associated HCC.

show abstract

“…Moreover, there are still some restrictions in access to DAA-based therapy, related to hepatic fibrosis. Confirmed viraemic prevalence is about 0.9%, and the rate of anti-HCV according to different studies is between 1.2 and 2.8% [22,23,. Despite all these facts, experts in Lithuania are optimistic to achieve the WHO target by 2030.…”

Section: Discussionmentioning

confidence: 99%

How close are we to hepatitis C virus elimination in Central Europe?

Flisiak¹,

Fraňková²,

Grgurević³

et al. 2020

ceh

View full text Add to dashboard Cite

Aim of the study: To collect and analyse data obtained from HCV opinion leaders/experts from central European countries, on factors which can affect the WHO target of HCV elimination by 2030. Material and methods: Data were collected from opinion leaders/experts involved in management of HCV infections in Central European countries which participated in 9 th Conference of the Central European Hepatologic Collaboration (Warsaw, 10-11 October 2019). A dedicated questionnaire collected current information related to HCV elimination in Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia. Results: The HCV prevalence rate in particular countries varied from 0.2% to 1.7%. In most central European countries all the HCV infected population is eligible for reimbursement of treatment. However, in some countries there are still some limitations related to the stage of the disease and people who inject drugs. All countries have access to at least one pangenotypic regimen. The most common barrier to HCV elimination in all countries is insufficient political will to establish priority for HCV. None of the reporting countries has established a national screening programme. Conclusions: Access to therapy for HCV is similar and the majority of patients in Central Europe can be treated according to the current guidelines. Unfortunately there are still some limitations and a lack of political will to implement national screening programmes. According to collected data HCV elimination will not be possible in the region by 2030.

show abstract

Anti-HCV prevalence in the general population of Lithuania

Cited by 13 publications

References 50 publications

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C VirusAssociated Hepatocellular Carcinomas

How close are we to hepatitis C virus elimination in Central Europe?

Contact Info

Product

Resources

About